Study of 99 million vaccinated individuals confirms pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis

Since declaration of the COVID-19 pandemic by the World Health Organization (WHO) on March 11, 2020 more than 13.5 billion doses of COVID-19 vaccines have been administered worldwide; and as of November 2023, at least 70.5 % of the world’s population had received at least one dose of a COVID-19 vaccine.

This study was a multi-country analysis that confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis. Other potential safety signals that require further investigation were also identified.

Largest-ever COVID vaccine study links shot to small increase in heart and brain conditions | Fox News

COVID-19 vaccine linked to possible health issues, study finds - NEWS NATION

SOURCE STUDY ...

COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals - ScienceDirect

BACKGROUND ...

Clinical Considerations: Myocarditis after COVID-19 Vaccines | CDC

Investigating Long-Term Effects of Myocarditis | CDC

GBS (Guillain-Barré Syndrome) and Vaccines | Vaccine Safety | CDC

Webinar April 15, 2021 - Johnson & Johnson/Janssen COVID-19 Vaccine and Cerebral Venous Sinus Thrombosis with Thrombocytopenia – Update for Clinicians on Early Detection and Treatment

Search Results | CDC - cerebral venous sinus thrombosis

REFERENCE ...

Heart Inflammation - Myocarditis | NHLBI, NIH